Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreatic Neoplasms | 71 | 2023 | 5446 | 3.800 |
Why?
|
Rectal Neoplasms | 28 | 2025 | 1183 | 2.990 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 88 | 2023 | 11878 | 2.840 |
Why?
|
Adenocarcinoma | 54 | 2025 | 6395 | 2.500 |
Why?
|
Deoxycytidine | 34 | 2020 | 887 | 2.310 |
Why?
|
Carcinoma, Pancreatic Ductal | 25 | 2023 | 1757 | 2.190 |
Why?
|
Neoadjuvant Therapy | 38 | 2025 | 2907 | 2.080 |
Why?
|
Fluorouracil | 54 | 2023 | 1652 | 1.880 |
Why?
|
Colorectal Neoplasms | 36 | 2023 | 6974 | 1.850 |
Why?
|
Peritoneal Neoplasms | 7 | 2022 | 714 | 1.770 |
Why?
|
Anus Neoplasms | 13 | 2020 | 336 | 1.640 |
Why?
|
Camptothecin | 20 | 2017 | 600 | 1.500 |
Why?
|
Gastrointestinal Neoplasms | 14 | 2023 | 957 | 1.400 |
Why?
|
Leucovorin | 27 | 2023 | 643 | 1.310 |
Why?
|
Organoplatinum Compounds | 22 | 2017 | 408 | 1.110 |
Why?
|
Antineoplastic Agents | 46 | 2023 | 13676 | 1.090 |
Why?
|
Liver Neoplasms | 25 | 2019 | 4362 | 0.980 |
Why?
|
Hyperthermia, Induced | 3 | 2021 | 416 | 0.960 |
Why?
|
Colonic Neoplasms | 13 | 2018 | 2541 | 0.950 |
Why?
|
Combined Modality Therapy | 31 | 2022 | 8542 | 0.910 |
Why?
|
Bile Duct Neoplasms | 10 | 2024 | 614 | 0.910 |
Why?
|
Carcinoma, Hepatocellular | 15 | 2019 | 2333 | 0.900 |
Why?
|
Neoplasm Staging | 46 | 2021 | 11244 | 0.840 |
Why?
|
Cholangiocarcinoma | 9 | 2024 | 561 | 0.790 |
Why?
|
Infusion Pumps | 1 | 2022 | 163 | 0.760 |
Why?
|
Hepatic Artery | 1 | 2022 | 232 | 0.740 |
Why?
|
Maximum Tolerated Dose | 23 | 2023 | 899 | 0.710 |
Why?
|
Paclitaxel | 7 | 2020 | 1733 | 0.680 |
Why?
|
Albumins | 3 | 2020 | 577 | 0.650 |
Why?
|
Neoplasms | 38 | 2022 | 22371 | 0.650 |
Why?
|
Stomach Neoplasms | 8 | 2021 | 1481 | 0.640 |
Why?
|
Neoplasm Recurrence, Local | 21 | 2021 | 9419 | 0.630 |
Why?
|
ras Proteins | 9 | 2014 | 1058 | 0.610 |
Why?
|
Chemotherapy, Adjuvant | 17 | 2020 | 3556 | 0.590 |
Why?
|
Medical Oncology | 4 | 2020 | 2346 | 0.590 |
Why?
|
Mitomycin | 5 | 2019 | 261 | 0.580 |
Why?
|
Antimetabolites, Antineoplastic | 12 | 2015 | 646 | 0.570 |
Why?
|
Middle Aged | 178 | 2025 | 223492 | 0.560 |
Why?
|
Humans | 269 | 2025 | 768166 | 0.560 |
Why?
|
Aged | 157 | 2025 | 171504 | 0.550 |
Why?
|
Lymphopenia | 3 | 2025 | 300 | 0.540 |
Why?
|
Dioxoles | 5 | 2005 | 96 | 0.540 |
Why?
|
Pseudomyxoma Peritonei | 2 | 2013 | 21 | 0.530 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2019 | 282 | 0.520 |
Why?
|
Proto-Oncogene Proteins B-raf | 11 | 2023 | 2059 | 0.510 |
Why?
|
Disease-Free Survival | 27 | 2019 | 6847 | 0.500 |
Why?
|
Neoplasm Metastasis | 21 | 2020 | 4912 | 0.500 |
Why?
|
Carboxylesterase | 1 | 2015 | 31 | 0.500 |
Why?
|
Male | 192 | 2025 | 364719 | 0.490 |
Why?
|
Isoquinolines | 5 | 2005 | 354 | 0.480 |
Why?
|
Survival Rate | 31 | 2024 | 12840 | 0.480 |
Why?
|
Burnout, Professional | 1 | 2023 | 711 | 0.480 |
Why?
|
Carcinoma | 4 | 2016 | 2332 | 0.480 |
Why?
|
Aged, 80 and over | 78 | 2024 | 59629 | 0.460 |
Why?
|
Esophageal Neoplasms | 8 | 2021 | 1668 | 0.460 |
Why?
|
Female | 186 | 2025 | 397192 | 0.440 |
Why?
|
Standard of Care | 3 | 2022 | 568 | 0.440 |
Why?
|
Antibodies, Monoclonal | 13 | 2020 | 9263 | 0.430 |
Why?
|
Treatment Outcome | 65 | 2023 | 65371 | 0.410 |
Why?
|
Antineoplastic Agents, Alkylating | 6 | 2009 | 614 | 0.400 |
Why?
|
Proto-Oncogene Proteins | 10 | 2014 | 4528 | 0.400 |
Why?
|
Adult | 128 | 2025 | 223646 | 0.380 |
Why?
|
Taxoids | 4 | 2006 | 667 | 0.380 |
Why?
|
Carcinoma, Squamous Cell | 6 | 2020 | 4058 | 0.370 |
Why?
|
Peritoneum | 1 | 2012 | 230 | 0.370 |
Why?
|
Sirolimus | 5 | 2013 | 1540 | 0.370 |
Why?
|
Palliative Care | 8 | 2022 | 3643 | 0.360 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2012 | 681 | 0.360 |
Why?
|
Prognosis | 38 | 2025 | 30010 | 0.360 |
Why?
|
Lung Neoplasms | 9 | 2020 | 13586 | 0.360 |
Why?
|
Community-Institutional Relations | 1 | 2012 | 209 | 0.360 |
Why?
|
Boronic Acids | 4 | 2008 | 915 | 0.360 |
Why?
|
Cecal Neoplasms | 1 | 2010 | 27 | 0.350 |
Why?
|
Community-Based Participatory Research | 1 | 2012 | 223 | 0.350 |
Why?
|
Pancreatectomy | 7 | 2023 | 825 | 0.350 |
Why?
|
Clinical Trials as Topic | 5 | 2020 | 8054 | 0.350 |
Why?
|
Heparin | 1 | 2017 | 1636 | 0.350 |
Why?
|
Neoplastic Cells, Circulating | 4 | 2020 | 952 | 0.340 |
Why?
|
Medication Errors | 1 | 2016 | 786 | 0.340 |
Why?
|
Carcinoid Tumor | 5 | 2018 | 225 | 0.330 |
Why?
|
Pyrazines | 4 | 2008 | 1205 | 0.320 |
Why?
|
Mutation | 21 | 2023 | 30238 | 0.310 |
Why?
|
Infusions, Intravenous | 18 | 2014 | 2230 | 0.300 |
Why?
|
Angiogenesis Inhibitors | 10 | 2014 | 2056 | 0.300 |
Why?
|
Drug Administration Schedule | 21 | 2015 | 4860 | 0.290 |
Why?
|
Kaplan-Meier Estimate | 13 | 2025 | 6526 | 0.270 |
Why?
|
Pyrroles | 5 | 2014 | 1124 | 0.270 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 9 | 2015 | 1767 | 0.270 |
Why?
|
Positron-Emission Tomography | 11 | 2022 | 6669 | 0.260 |
Why?
|
Neuroendocrine Tumors | 7 | 2013 | 659 | 0.260 |
Why?
|
Academic Medical Centers | 2 | 2016 | 2784 | 0.250 |
Why?
|
Survival Analysis | 25 | 2019 | 10101 | 0.250 |
Why?
|
Quinazolines | 9 | 2013 | 1373 | 0.250 |
Why?
|
Gene Amplification | 3 | 2020 | 1095 | 0.240 |
Why?
|
Pancreas | 2 | 2017 | 1700 | 0.240 |
Why?
|
Massachusetts | 12 | 2020 | 8890 | 0.240 |
Why?
|
Radiotherapy | 6 | 2021 | 1502 | 0.240 |
Why?
|
Radiotherapy Dosage | 13 | 2019 | 2916 | 0.240 |
Why?
|
Radiotherapy, Intensity-Modulated | 5 | 2018 | 798 | 0.230 |
Why?
|
Retrospective Studies | 46 | 2025 | 81762 | 0.230 |
Why?
|
Hospitalization | 9 | 2022 | 10840 | 0.230 |
Why?
|
Biliary Tract Neoplasms | 2 | 2020 | 187 | 0.230 |
Why?
|
Indoles | 5 | 2011 | 1836 | 0.220 |
Why?
|
Alkyl and Aryl Transferases | 1 | 2004 | 89 | 0.220 |
Why?
|
Intraoperative Care | 2 | 2018 | 770 | 0.220 |
Why?
|
Dose-Response Relationship, Drug | 17 | 2023 | 10760 | 0.220 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2020 | 8647 | 0.210 |
Why?
|
Isocitrate Dehydrogenase | 3 | 2015 | 951 | 0.210 |
Why?
|
Quality of Life | 10 | 2020 | 13490 | 0.210 |
Why?
|
Imidazoles | 3 | 2015 | 1169 | 0.210 |
Why?
|
Follow-Up Studies | 22 | 2024 | 39348 | 0.210 |
Why?
|
Disease Progression | 18 | 2022 | 13671 | 0.210 |
Why?
|
Photons | 2 | 2019 | 594 | 0.200 |
Why?
|
Bile Ducts, Intrahepatic | 4 | 2014 | 304 | 0.200 |
Why?
|
Drug Resistance, Neoplasm | 12 | 2020 | 5341 | 0.200 |
Why?
|
Infusions, Intra-Arterial | 1 | 2022 | 220 | 0.200 |
Why?
|
Immunoconjugates | 2 | 2023 | 975 | 0.200 |
Why?
|
Anal Canal | 4 | 2020 | 376 | 0.200 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2022 | 223 | 0.190 |
Why?
|
Losartan | 2 | 2023 | 262 | 0.190 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2006 | 489 | 0.190 |
Why?
|
Cisplatin | 6 | 2013 | 1660 | 0.190 |
Why?
|
Benzodiazepines | 2 | 2005 | 1138 | 0.190 |
Why?
|
Radiodermatitis | 2 | 2019 | 61 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-met | 3 | 2020 | 564 | 0.180 |
Why?
|
Rectum | 2 | 2018 | 900 | 0.180 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2000 | 330 | 0.180 |
Why?
|
Radiotherapy, Adjuvant | 7 | 2016 | 1791 | 0.180 |
Why?
|
Surge Capacity | 1 | 2020 | 49 | 0.180 |
Why?
|
Feasibility Studies | 7 | 2023 | 5315 | 0.170 |
Why?
|
Randomized Controlled Trials as Topic | 8 | 2022 | 10399 | 0.170 |
Why?
|
Phosphatidylinositol 3-Kinases | 6 | 2014 | 2885 | 0.170 |
Why?
|
HMGA2 Protein | 1 | 2020 | 101 | 0.170 |
Why?
|
Neoplasm, Residual | 3 | 2021 | 1015 | 0.170 |
Why?
|
Colectomy | 3 | 2011 | 696 | 0.170 |
Why?
|
Patient Care Team | 2 | 2020 | 2523 | 0.160 |
Why?
|
Radiation Injuries | 5 | 2020 | 1198 | 0.160 |
Why?
|
Heparitin Sulfate | 1 | 2020 | 223 | 0.160 |
Why?
|
Drug Delivery Systems | 1 | 2010 | 2232 | 0.160 |
Why?
|
Neutropenia | 5 | 2017 | 892 | 0.160 |
Why?
|
Practice Guidelines as Topic | 6 | 2020 | 7454 | 0.150 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 117 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 354 | 0.150 |
Why?
|
Carcinoma, Small Cell | 1 | 2000 | 419 | 0.150 |
Why?
|
Gallbladder Neoplasms | 2 | 2011 | 190 | 0.150 |
Why?
|
Organoids | 2 | 2022 | 743 | 0.150 |
Why?
|
Chromogranins | 1 | 2018 | 160 | 0.140 |
Why?
|
Administration, Oral | 11 | 2014 | 4030 | 0.140 |
Why?
|
Physician's Role | 2 | 2020 | 925 | 0.140 |
Why?
|
Personal Satisfaction | 1 | 2022 | 643 | 0.140 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2020 | 423 | 0.140 |
Why?
|
Chemokine CCL2 | 1 | 2019 | 605 | 0.140 |
Why?
|
Angiotensins | 1 | 2017 | 141 | 0.140 |
Why?
|
Liver Failure | 1 | 2019 | 252 | 0.140 |
Why?
|
GTP-Binding Protein alpha Subunits, Gs | 1 | 2018 | 194 | 0.130 |
Why?
|
Tetrahydroisoquinolines | 5 | 2005 | 81 | 0.130 |
Why?
|
Patient-Centered Care | 2 | 2019 | 1444 | 0.130 |
Why?
|
Appendiceal Neoplasms | 1 | 2018 | 155 | 0.130 |
Why?
|
Sarcoma | 5 | 2005 | 1806 | 0.130 |
Why?
|
Models, Chemical | 5 | 2007 | 611 | 0.130 |
Why?
|
Carcinoembryonic Antigen | 3 | 2014 | 338 | 0.130 |
Why?
|
Genetic Heterogeneity | 2 | 2019 | 736 | 0.130 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2018 | 481 | 0.130 |
Why?
|
Patient Acceptance of Health Care | 3 | 2019 | 3231 | 0.130 |
Why?
|
Cellulitis | 1 | 2017 | 206 | 0.130 |
Why?
|
Laparotomy | 1 | 2018 | 458 | 0.130 |
Why?
|
Hospitals, General | 1 | 2020 | 809 | 0.130 |
Why?
|
Protein Kinase Inhibitors | 9 | 2023 | 5703 | 0.130 |
Why?
|
Fluorodeoxyglucose F18 | 5 | 2022 | 2055 | 0.130 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2016 | 212 | 0.120 |
Why?
|
Tumor Microenvironment | 4 | 2023 | 3948 | 0.120 |
Why?
|
Propensity Score | 2 | 2023 | 1969 | 0.120 |
Why?
|
Prospective Studies | 20 | 2021 | 54926 | 0.120 |
Why?
|
RNA, Neoplasm | 2 | 2017 | 749 | 0.120 |
Why?
|
Guanylate Cyclase | 1 | 2016 | 206 | 0.120 |
Why?
|
Area Under Curve | 7 | 2005 | 1643 | 0.120 |
Why?
|
Resuscitation Orders | 1 | 2017 | 271 | 0.120 |
Why?
|
Time Factors | 13 | 2019 | 40218 | 0.120 |
Why?
|
Phosphoramide Mustards | 1 | 2014 | 18 | 0.120 |
Why?
|
Farnesyltranstransferase | 2 | 2005 | 71 | 0.120 |
Why?
|
Pyrimidines | 4 | 2016 | 3048 | 0.120 |
Why?
|
Goblet Cells | 1 | 2018 | 300 | 0.120 |
Why?
|
Phenylurea Compounds | 2 | 2016 | 531 | 0.120 |
Why?
|
Bone Marrow Diseases | 1 | 2017 | 234 | 0.120 |
Why?
|
Early Detection of Cancer | 3 | 2019 | 3239 | 0.120 |
Why?
|
Patient Selection | 3 | 2012 | 4260 | 0.120 |
Why?
|
Affect | 2 | 2020 | 1495 | 0.120 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2013 | 1627 | 0.120 |
Why?
|
Collagen | 2 | 2002 | 2643 | 0.120 |
Why?
|
Endostatins | 3 | 2006 | 167 | 0.110 |
Why?
|
Triazoles | 1 | 2020 | 904 | 0.110 |
Why?
|
Esophagogastric Junction | 3 | 2020 | 351 | 0.110 |
Why?
|
Magnetic Resonance Imaging | 9 | 2022 | 36743 | 0.110 |
Why?
|
DNA, Neoplasm | 1 | 2019 | 1744 | 0.110 |
Why?
|
Spermine | 1 | 2013 | 70 | 0.110 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2015 | 331 | 0.110 |
Why?
|
Nitroimidazoles | 1 | 2014 | 118 | 0.110 |
Why?
|
Small Molecule Libraries | 1 | 2019 | 742 | 0.110 |
Why?
|
Lymphatic Metastasis | 4 | 2017 | 2914 | 0.110 |
Why?
|
Precancerous Conditions | 2 | 2017 | 985 | 0.110 |
Why?
|
Ethics, Medical | 1 | 1999 | 785 | 0.110 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2017 | 526 | 0.110 |
Why?
|
Treatment Failure | 5 | 2019 | 2661 | 0.110 |
Why?
|
Sexual Behavior | 2 | 2020 | 2197 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 9 | 2021 | 20760 | 0.100 |
Why?
|
Blood Vessels | 1 | 2018 | 1110 | 0.100 |
Why?
|
Risk Management | 1 | 2016 | 558 | 0.100 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15948 | 0.100 |
Why?
|
Glutarates | 1 | 2014 | 242 | 0.100 |
Why?
|
Dacarbazine | 3 | 2013 | 552 | 0.100 |
Why?
|
Pyridines | 3 | 2021 | 2894 | 0.100 |
Why?
|
Carcinoma, Papillary | 1 | 2017 | 793 | 0.100 |
Why?
|
Cross Infection | 1 | 2021 | 1426 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2011 | 2062 | 0.100 |
Why?
|
Epirubicin | 2 | 2016 | 82 | 0.100 |
Why?
|
beta Karyopherins | 1 | 2011 | 46 | 0.090 |
Why?
|
DNA Mutational Analysis | 4 | 2014 | 4120 | 0.090 |
Why?
|
RNA-Binding Proteins | 1 | 2020 | 1890 | 0.090 |
Why?
|
Vena Cava Filters | 1 | 2014 | 270 | 0.090 |
Why?
|
Cell Separation | 1 | 2017 | 1728 | 0.090 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2018 | 1679 | 0.090 |
Why?
|
Length of Stay | 4 | 2018 | 6498 | 0.090 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 942 | 0.090 |
Why?
|
Constriction, Pathologic | 1 | 2014 | 1104 | 0.090 |
Why?
|
Terminology as Topic | 1 | 2018 | 1542 | 0.090 |
Why?
|
Protein Kinases | 2 | 2008 | 1611 | 0.090 |
Why?
|
Appointments and Schedules | 1 | 2015 | 443 | 0.090 |
Why?
|
Mental Disorders | 2 | 2022 | 6874 | 0.090 |
Why?
|
Hospice Care | 1 | 2017 | 678 | 0.090 |
Why?
|
Salvage Therapy | 3 | 2007 | 1273 | 0.090 |
Why?
|
Diagnosis, Differential | 3 | 2013 | 13014 | 0.090 |
Why?
|
Colon, Sigmoid | 1 | 2011 | 124 | 0.090 |
Why?
|
Doxorubicin | 4 | 2006 | 2234 | 0.090 |
Why?
|
Sensory Receptor Cells | 1 | 2015 | 508 | 0.090 |
Why?
|
Enzyme Inhibitors | 3 | 2005 | 3728 | 0.090 |
Why?
|
Peptide Fragments | 2 | 2002 | 5151 | 0.090 |
Why?
|
Antineoplastic Agents, Phytogenic | 3 | 2005 | 622 | 0.090 |
Why?
|
Proportional Hazards Models | 5 | 2019 | 12543 | 0.090 |
Why?
|
Hedgehog Proteins | 1 | 2014 | 771 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2020 | 3671 | 0.080 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2018 | 2846 | 0.080 |
Why?
|
Signal Transduction | 7 | 2018 | 23645 | 0.080 |
Why?
|
Lipid Metabolism | 1 | 2018 | 1904 | 0.080 |
Why?
|
Depression | 3 | 2018 | 8230 | 0.080 |
Why?
|
Thrombosis | 1 | 2023 | 2957 | 0.080 |
Why?
|
Piperazines | 3 | 2021 | 2554 | 0.080 |
Why?
|
Vulnerable Populations | 1 | 2015 | 718 | 0.080 |
Why?
|
Device Removal | 1 | 2014 | 643 | 0.080 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2015 | 716 | 0.080 |
Why?
|
DNA Damage | 1 | 2019 | 2469 | 0.080 |
Why?
|
Vagina | 1 | 2014 | 850 | 0.080 |
Why?
|
Polymorphism, Genetic | 3 | 2008 | 4249 | 0.080 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 2009 | 82 | 0.080 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 3 | 2010 | 662 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2018 | 2008 | 0.080 |
Why?
|
Microsatellite Instability | 2 | 2015 | 726 | 0.080 |
Why?
|
CA-19-9 Antigen | 2 | 2022 | 109 | 0.080 |
Why?
|
Brain Neoplasms | 2 | 2021 | 9118 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2022 | 2954 | 0.080 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 4 | 2014 | 905 | 0.080 |
Why?
|
Wnt Proteins | 1 | 2012 | 725 | 0.080 |
Why?
|
Europe | 1 | 2015 | 3436 | 0.080 |
Why?
|
Patient Discharge | 2 | 2020 | 3479 | 0.070 |
Why?
|
Intestine, Small | 2 | 2012 | 1217 | 0.070 |
Why?
|
Whole Body Imaging | 1 | 2010 | 284 | 0.070 |
Why?
|
Radiosurgery | 1 | 2017 | 1330 | 0.070 |
Why?
|
Radiopharmaceuticals | 3 | 2022 | 2735 | 0.070 |
Why?
|
Receptor, erbB-2 | 1 | 2018 | 2603 | 0.070 |
Why?
|
Tubulin | 1 | 2011 | 695 | 0.070 |
Why?
|
Surgical Wound Dehiscence | 1 | 2009 | 216 | 0.070 |
Why?
|
RNA, Messenger | 4 | 2017 | 12800 | 0.070 |
Why?
|
Disease Management | 2 | 2016 | 2536 | 0.070 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2012 | 329 | 0.070 |
Why?
|
Floxuridine | 1 | 2006 | 44 | 0.070 |
Why?
|
Pyrimidinones | 2 | 2023 | 386 | 0.070 |
Why?
|
Respiration | 1 | 2013 | 1665 | 0.070 |
Why?
|
Cohort Studies | 11 | 2020 | 41754 | 0.070 |
Why?
|
Forecasting | 1 | 2016 | 2945 | 0.070 |
Why?
|
Oxonic Acid | 1 | 2006 | 32 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2010 | 3514 | 0.070 |
Why?
|
Tegafur | 1 | 2006 | 40 | 0.070 |
Why?
|
GTP Phosphohydrolases | 3 | 2014 | 525 | 0.070 |
Why?
|
Receptors, Growth Factor | 1 | 2007 | 324 | 0.070 |
Why?
|
Tumor Burden | 4 | 2017 | 1906 | 0.070 |
Why?
|
Adaptation, Psychological | 1 | 2017 | 2663 | 0.070 |
Why?
|
Antidepressive Agents | 1 | 2018 | 2913 | 0.070 |
Why?
|
Oligopeptides | 2 | 2016 | 1194 | 0.060 |
Why?
|
Digestive System Neoplasms | 1 | 2006 | 82 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2008 | 362 | 0.060 |
Why?
|
Thalidomide | 3 | 2006 | 886 | 0.060 |
Why?
|
Double-Blind Method | 1 | 2020 | 12465 | 0.060 |
Why?
|
Soft Tissue Neoplasms | 2 | 2005 | 1164 | 0.060 |
Why?
|
Streptozocin | 2 | 2004 | 190 | 0.060 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2006 | 128 | 0.060 |
Why?
|
Ifosfamide | 1 | 2006 | 233 | 0.060 |
Why?
|
Self Care | 2 | 2022 | 799 | 0.060 |
Why?
|
Pancreaticoduodenectomy | 3 | 2015 | 515 | 0.060 |
Why?
|
Epithelial Cells | 1 | 2017 | 3703 | 0.060 |
Why?
|
Gastrointestinal Diseases | 2 | 2012 | 1206 | 0.060 |
Why?
|
Superoxide Dismutase | 1 | 2008 | 596 | 0.060 |
Why?
|
alpha-Fetoproteins | 1 | 2006 | 229 | 0.060 |
Why?
|
Hydrazines | 1 | 2007 | 223 | 0.060 |
Why?
|
Haemophilus Vaccines | 1 | 2005 | 71 | 0.060 |
Why?
|
raf Kinases | 1 | 2005 | 117 | 0.060 |
Why?
|
Neoplasm Invasiveness | 3 | 2017 | 3620 | 0.060 |
Why?
|
Mice, Inbred NOD | 2 | 2020 | 1837 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 5889 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2011 | 2457 | 0.060 |
Why?
|
Peroxidase | 1 | 2008 | 610 | 0.060 |
Why?
|
Benzenesulfonates | 1 | 2005 | 170 | 0.060 |
Why?
|
Tetanus Toxoid | 1 | 2005 | 188 | 0.060 |
Why?
|
src-Family Kinases | 1 | 2007 | 539 | 0.060 |
Why?
|
Perioperative Care | 1 | 2012 | 1043 | 0.060 |
Why?
|
Risk Factors | 8 | 2016 | 74944 | 0.060 |
Why?
|
Vinblastine | 1 | 2006 | 487 | 0.060 |
Why?
|
Patient Compliance | 1 | 2015 | 2697 | 0.060 |
Why?
|
MicroRNAs | 1 | 2020 | 3803 | 0.060 |
Why?
|
Dihydrouracil Dehydrogenase (NADP) | 1 | 2004 | 17 | 0.060 |
Why?
|
Pyridones | 2 | 2023 | 819 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5706 | 0.060 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 246 | 0.060 |
Why?
|
Thymidylate Synthase | 1 | 2004 | 74 | 0.060 |
Why?
|
Purine Nucleosides | 1 | 2003 | 30 | 0.060 |
Why?
|
Catheterization, Central Venous | 1 | 2009 | 537 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2004 | 725 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2017 | 4055 | 0.060 |
Why?
|
Pain | 3 | 2014 | 5100 | 0.060 |
Why?
|
Genes, ras | 2 | 2018 | 663 | 0.050 |
Why?
|
Pheochromocytoma | 1 | 2006 | 328 | 0.050 |
Why?
|
Pandemics | 2 | 2021 | 8748 | 0.050 |
Why?
|
Hospital Mortality | 1 | 2017 | 5349 | 0.050 |
Why?
|
Evidence-Based Medicine | 2 | 2012 | 3706 | 0.050 |
Why?
|
Adenomatous Polyposis Coli Protein | 2 | 2014 | 182 | 0.050 |
Why?
|
Mesenteric Veins | 1 | 2023 | 87 | 0.050 |
Why?
|
Staurosporine | 1 | 2004 | 241 | 0.050 |
Why?
|
Proteasome Endopeptidase Complex | 2 | 2006 | 1319 | 0.050 |
Why?
|
Morpholines | 1 | 2006 | 584 | 0.050 |
Why?
|
Drug Synergism | 1 | 2007 | 1760 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3115 | 0.050 |
Why?
|
Multivariate Analysis | 4 | 2019 | 12077 | 0.050 |
Why?
|
Radioisotope Teletherapy | 1 | 2002 | 15 | 0.050 |
Why?
|
Lymph Node Excision | 1 | 2008 | 1271 | 0.050 |
Why?
|
Chromans | 1 | 2002 | 116 | 0.050 |
Why?
|
Mitomycins | 1 | 2002 | 46 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3238 | 0.050 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2006 | 343 | 0.050 |
Why?
|
CpG Islands | 1 | 2007 | 1208 | 0.050 |
Why?
|
Risk Assessment | 6 | 2017 | 24315 | 0.050 |
Why?
|
Pilot Projects | 3 | 2021 | 8741 | 0.050 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2020 | 2521 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5432 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2020 | 6124 | 0.050 |
Why?
|
Life Cycle Stages | 1 | 2022 | 161 | 0.050 |
Why?
|
Immunohistochemistry | 3 | 2010 | 11095 | 0.050 |
Why?
|
Genotype | 5 | 2017 | 13045 | 0.050 |
Why?
|
Pneumococcal Vaccines | 1 | 2005 | 414 | 0.050 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2004 | 335 | 0.050 |
Why?
|
Venous Thromboembolism | 1 | 2014 | 1883 | 0.050 |
Why?
|
Neoplasm Transplantation | 2 | 2017 | 2014 | 0.050 |
Why?
|
Fractals | 1 | 2021 | 127 | 0.050 |
Why?
|
Age Factors | 5 | 2023 | 18412 | 0.050 |
Why?
|
Lamivudine | 1 | 2022 | 367 | 0.040 |
Why?
|
Physician-Patient Relations | 1 | 2014 | 3269 | 0.040 |
Why?
|
Portal Vein | 1 | 2023 | 435 | 0.040 |
Why?
|
Toxicity Tests | 1 | 2001 | 114 | 0.040 |
Why?
|
Anxiety | 3 | 2022 | 4672 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2003 | 1377 | 0.040 |
Why?
|
United States | 4 | 2019 | 73039 | 0.040 |
Why?
|
Genes, MHC Class I | 1 | 2021 | 235 | 0.040 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2006 | 735 | 0.040 |
Why?
|
Hematologic Tests | 1 | 2021 | 239 | 0.040 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2018 | 4640 | 0.040 |
Why?
|
Censuses | 1 | 2021 | 198 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 637 | 0.040 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2002 | 348 | 0.040 |
Why?
|
Anemia, Hemolytic | 1 | 2001 | 164 | 0.040 |
Why?
|
Predictive Value of Tests | 4 | 2021 | 15454 | 0.040 |
Why?
|
Preoperative Period | 1 | 2022 | 565 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2021 | 785 | 0.040 |
Why?
|
Thiazolidinediones | 1 | 2002 | 461 | 0.040 |
Why?
|
Blood Loss, Surgical | 1 | 2023 | 642 | 0.040 |
Why?
|
Aspartate Aminotransferases | 1 | 2001 | 414 | 0.040 |
Why?
|
Cell Line, Tumor | 4 | 2020 | 17140 | 0.040 |
Why?
|
Inpatients | 2 | 2021 | 2566 | 0.040 |
Why?
|
Collagen Type XVIII | 1 | 1999 | 52 | 0.040 |
Why?
|
Colostomy | 1 | 2019 | 106 | 0.040 |
Why?
|
Enzyme Repression | 1 | 2018 | 30 | 0.040 |
Why?
|
Intraoperative Period | 2 | 2013 | 513 | 0.040 |
Why?
|
Pneumonectomy | 1 | 2006 | 1156 | 0.040 |
Why?
|
Young Adult | 8 | 2020 | 60066 | 0.040 |
Why?
|
Education, Medical, Continuing | 1 | 2004 | 829 | 0.040 |
Why?
|
Schizophrenia | 1 | 2017 | 6983 | 0.040 |
Why?
|
Interferons | 1 | 2022 | 720 | 0.040 |
Why?
|
Survivors | 1 | 2009 | 2381 | 0.040 |
Why?
|
Preoperative Care | 2 | 2013 | 2258 | 0.040 |
Why?
|
Safety | 3 | 2012 | 1159 | 0.040 |
Why?
|
Alanine Transaminase | 1 | 2001 | 606 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2000 | 640 | 0.040 |
Why?
|
Videoconferencing | 1 | 2020 | 209 | 0.040 |
Why?
|
Biopsy | 3 | 2018 | 6793 | 0.040 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 859 | 0.040 |
Why?
|
Wound Healing | 1 | 2009 | 2809 | 0.040 |
Why?
|
Interprofessional Relations | 1 | 2004 | 997 | 0.040 |
Why?
|
Cancer Vaccines | 1 | 2005 | 1041 | 0.040 |
Why?
|
Liver Function Tests | 2 | 2013 | 526 | 0.040 |
Why?
|
Mice, 129 Strain | 1 | 2018 | 369 | 0.040 |
Why?
|
Cause of Death | 2 | 2019 | 3721 | 0.040 |
Why?
|
Pyrrolidines | 1 | 2019 | 340 | 0.040 |
Why?
|
Transcription Factor TFIIIA | 1 | 2016 | 24 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 565 | 0.040 |
Why?
|
Animals | 9 | 2022 | 169246 | 0.040 |
Why?
|
Tumor Virus Infections | 1 | 2000 | 437 | 0.030 |
Why?
|
Radiography | 4 | 2010 | 6983 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2008 | 5797 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2006 | 2433 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 4 | 2018 | 18065 | 0.030 |
Why?
|
Sequence Analysis, RNA | 2 | 2017 | 2040 | 0.030 |
Why?
|
Education, Medical | 1 | 2008 | 1742 | 0.030 |
Why?
|
Caregivers | 2 | 2022 | 2302 | 0.030 |
Why?
|
Thrombocytopenia | 2 | 2006 | 1179 | 0.030 |
Why?
|
Transplantation, Heterologous | 2 | 2017 | 2393 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2000 | 879 | 0.030 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2016 | 109 | 0.030 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2020 | 364 | 0.030 |
Why?
|
Pelvis | 1 | 2020 | 736 | 0.030 |
Why?
|
Tumor Escape | 1 | 2019 | 372 | 0.030 |
Why?
|
Psychological Tests | 1 | 2018 | 643 | 0.030 |
Why?
|
Hep G2 Cells | 1 | 2017 | 378 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2023 | 1625 | 0.030 |
Why?
|
Autopsy | 1 | 2019 | 1011 | 0.030 |
Why?
|
Ontario | 2 | 2008 | 403 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 788 | 0.030 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2005 | 1250 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2005 | 2631 | 0.030 |
Why?
|
Mice, Mutant Strains | 1 | 2018 | 1754 | 0.030 |
Why?
|
Mice, SCID | 1 | 2020 | 2627 | 0.030 |
Why?
|
Thiazoles | 1 | 2002 | 1542 | 0.030 |
Why?
|
Oxaloacetates | 1 | 2014 | 5 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 1003 | 0.030 |
Why?
|
Antibodies | 1 | 2023 | 2421 | 0.030 |
Why?
|
Base Sequence | 3 | 2012 | 12421 | 0.030 |
Why?
|
Pelvic Bones | 1 | 2017 | 274 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2359 | 0.030 |
Why?
|
Incidence | 3 | 2021 | 21538 | 0.030 |
Why?
|
Spiral Cone-Beam Computed Tomography | 1 | 2015 | 32 | 0.030 |
Why?
|
Hospices | 1 | 2017 | 245 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2020 | 1443 | 0.030 |
Why?
|
Leadership | 1 | 2004 | 1397 | 0.030 |
Why?
|
Receptors, CXCR | 1 | 2014 | 52 | 0.030 |
Why?
|
Oximes | 1 | 2015 | 303 | 0.030 |
Why?
|
Gene Fusion | 1 | 2016 | 356 | 0.030 |
Why?
|
Exercise | 1 | 2011 | 5955 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2000 | 1140 | 0.030 |
Why?
|
Hepatectomy | 1 | 2017 | 588 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 162 | 0.030 |
Why?
|
Antigen-Presenting Cells | 1 | 2017 | 960 | 0.030 |
Why?
|
Molecular Targeted Therapy | 2 | 2015 | 2830 | 0.030 |
Why?
|
Cytarabine | 2 | 2010 | 695 | 0.030 |
Why?
|
Triage | 1 | 2020 | 997 | 0.030 |
Why?
|
DNA Primers | 2 | 2011 | 2828 | 0.030 |
Why?
|
Retreatment | 1 | 2014 | 598 | 0.030 |
Why?
|
Neoplasm Proteins | 2 | 2017 | 3603 | 0.030 |
Why?
|
Membrane Proteins | 3 | 2014 | 7876 | 0.030 |
Why?
|
Wnt2 Protein | 1 | 2012 | 28 | 0.030 |
Why?
|
Liver | 3 | 2007 | 7577 | 0.030 |
Why?
|
Contact Inhibition | 1 | 2012 | 46 | 0.030 |
Why?
|
Hepatocyte Growth Factor | 1 | 2014 | 268 | 0.030 |
Why?
|
Fatigue | 1 | 2020 | 1557 | 0.030 |
Why?
|
DNA Methylation | 1 | 2007 | 4428 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2022 | 9538 | 0.030 |
Why?
|
Diarrhea | 2 | 2012 | 1320 | 0.030 |
Why?
|
Hepatitis B, Chronic | 1 | 2017 | 413 | 0.030 |
Why?
|
Leukemia | 1 | 2000 | 1519 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1596 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2019 | 1361 | 0.020 |
Why?
|
Intestine, Large | 1 | 2012 | 69 | 0.020 |
Why?
|
Biopsy, Needle | 2 | 2010 | 1622 | 0.020 |
Why?
|
Lab-On-A-Chip Devices | 1 | 2017 | 445 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2012 | 5863 | 0.020 |
Why?
|
RNA | 1 | 2022 | 2720 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2019 | 1741 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 2017 | 1230 | 0.020 |
Why?
|
Models, Statistical | 2 | 2018 | 5107 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2018 | 2227 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2013 | 876 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2015 | 427 | 0.020 |
Why?
|
Patient Care Planning | 1 | 2017 | 905 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2019 | 1514 | 0.020 |
Why?
|
Reminder Systems | 1 | 2015 | 388 | 0.020 |
Why?
|
Sample Size | 1 | 2015 | 846 | 0.020 |
Why?
|
Needs Assessment | 1 | 2017 | 1141 | 0.020 |
Why?
|
Telephone | 1 | 2015 | 630 | 0.020 |
Why?
|
Case-Control Studies | 3 | 2017 | 22291 | 0.020 |
Why?
|
Gastrectomy | 1 | 2016 | 693 | 0.020 |
Why?
|
Membrane Transport Proteins | 1 | 2016 | 1037 | 0.020 |
Why?
|
Logistic Models | 2 | 2017 | 13290 | 0.020 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2012 | 252 | 0.020 |
Why?
|
Actuarial Analysis | 1 | 2010 | 370 | 0.020 |
Why?
|
Cell Cycle Proteins | 2 | 2016 | 3445 | 0.020 |
Why?
|
Urogenital System | 1 | 2010 | 88 | 0.020 |
Why?
|
SEER Program | 1 | 2016 | 1444 | 0.020 |
Why?
|
Defecation | 1 | 2012 | 191 | 0.020 |
Why?
|
Genes, Neoplasm | 1 | 2012 | 371 | 0.020 |
Why?
|
Adolescent | 4 | 2020 | 89169 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2022 | 14729 | 0.020 |
Why?
|
Somatostatin | 1 | 2012 | 458 | 0.020 |
Why?
|
Lymphatic Irradiation | 1 | 2010 | 115 | 0.020 |
Why?
|
Self Report | 1 | 2022 | 3773 | 0.020 |
Why?
|
Fatty Acids | 1 | 2018 | 1812 | 0.020 |
Why?
|
Health Status | 2 | 2017 | 4091 | 0.020 |
Why?
|
Immunotherapy | 2 | 2021 | 4755 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2017 | 21206 | 0.020 |
Why?
|
PTEN Phosphohydrolase | 1 | 2015 | 1120 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3073 | 0.020 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2017 | 997 | 0.020 |
Why?
|
Benzamides | 2 | 2006 | 1379 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 560 | 0.020 |
Why?
|
Transcription Factors | 2 | 2014 | 12168 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2022 | 3488 | 0.020 |
Why?
|
Diphosphonates | 1 | 2014 | 634 | 0.020 |
Why?
|
Recurrence | 2 | 2011 | 8509 | 0.020 |
Why?
|
Failure to Thrive | 1 | 2009 | 139 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2017 | 1967 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 130 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7214 | 0.020 |
Why?
|
Smoking | 1 | 2005 | 9092 | 0.020 |
Why?
|
Cost of Illness | 1 | 2018 | 1951 | 0.020 |
Why?
|
Cell Movement | 1 | 2020 | 5210 | 0.020 |
Why?
|
Drug Substitution | 1 | 2010 | 291 | 0.020 |
Why?
|
Papillomavirus Infections | 1 | 2000 | 1640 | 0.020 |
Why?
|
Psychometrics | 1 | 2017 | 3063 | 0.020 |
Why?
|
Cell Lineage | 1 | 2017 | 2575 | 0.020 |
Why?
|
Radiotherapy, Conformal | 1 | 2011 | 549 | 0.020 |
Why?
|
Prescriptions | 1 | 2010 | 388 | 0.020 |
Why?
|
Mice | 4 | 2017 | 82029 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2009 | 457 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2015 | 3611 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2017 | 6029 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2011 | 1606 | 0.020 |
Why?
|
Intraoperative Complications | 1 | 2013 | 1171 | 0.020 |
Why?
|
Bone Marrow | 1 | 2017 | 2935 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2010 | 498 | 0.020 |
Why?
|
Nausea | 1 | 2009 | 682 | 0.020 |
Why?
|
Demography | 1 | 2011 | 1641 | 0.020 |
Why?
|
Cell Count | 1 | 2010 | 1832 | 0.020 |
Why?
|
Digestive System Surgical Procedures | 1 | 2011 | 583 | 0.020 |
Why?
|
Carcinoma, Islet Cell | 1 | 2006 | 21 | 0.020 |
Why?
|
Acute Disease | 1 | 2017 | 7243 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 2017 | 1960 | 0.020 |
Why?
|
Upper Gastrointestinal Tract | 1 | 2006 | 46 | 0.020 |
Why?
|
Vomiting | 1 | 2009 | 655 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2012 | 1397 | 0.020 |
Why?
|
Risk | 2 | 2008 | 9613 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2012 | 3590 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2019 | 5536 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2017 | 3474 | 0.020 |
Why?
|
Patient Readmission | 1 | 2020 | 3288 | 0.020 |
Why?
|
Antigens, Neoplasm | 2 | 2005 | 1997 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2018 | 9561 | 0.020 |
Why?
|
Terminal Care | 1 | 2017 | 1770 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2017 | 2540 | 0.020 |
Why?
|
Pyridoxal Phosphate | 1 | 2005 | 123 | 0.020 |
Why?
|
Self Administration | 1 | 2006 | 386 | 0.020 |
Why?
|
Mice, Nude | 1 | 2011 | 3623 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2002 | 4916 | 0.010 |
Why?
|
Recombinant Proteins | 2 | 2006 | 6514 | 0.010 |
Why?
|
Injections, Subcutaneous | 1 | 2006 | 687 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2020 | 14488 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2013 | 6229 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 1999 | 3929 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2005 | 317 | 0.010 |
Why?
|
Edetic Acid | 1 | 2005 | 278 | 0.010 |
Why?
|
Gastrointestinal Tract | 1 | 2010 | 840 | 0.010 |
Why?
|
Comorbidity | 2 | 2009 | 10590 | 0.010 |
Why?
|
MAP Kinase Signaling System | 1 | 2011 | 1494 | 0.010 |
Why?
|
Single-Blind Method | 1 | 2008 | 1587 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 379 | 0.010 |
Why?
|
Peripheral Nervous System | 1 | 2005 | 151 | 0.010 |
Why?
|
Continuity of Patient Care | 1 | 2011 | 1078 | 0.010 |
Why?
|
Hemoglobins | 1 | 2010 | 1531 | 0.010 |
Why?
|
Nurses | 1 | 2014 | 2501 | 0.010 |
Why?
|
Hydroxyindoleacetic Acid | 1 | 2004 | 94 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2862 | 0.010 |
Why?
|
Antipsychotic Agents | 1 | 2017 | 3081 | 0.010 |
Why?
|
Life Tables | 1 | 2004 | 367 | 0.010 |
Why?
|
Terminally Ill | 1 | 2005 | 240 | 0.010 |
Why?
|
Vaccines, Conjugate | 1 | 2005 | 334 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14783 | 0.010 |
Why?
|
Niacinamide | 1 | 2005 | 418 | 0.010 |
Why?
|
Octreotide | 1 | 2004 | 156 | 0.010 |
Why?
|
Stomach | 1 | 2007 | 701 | 0.010 |
Why?
|
Insurance, Health | 1 | 2015 | 2517 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 3428 | 0.010 |
Why?
|
Cell Survival | 1 | 2012 | 5777 | 0.010 |
Why?
|
Leukocytes | 1 | 2010 | 2035 | 0.010 |
Why?
|
Antigens, CD34 | 1 | 2004 | 657 | 0.010 |
Why?
|
Drugs, Investigational | 1 | 2004 | 211 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7598 | 0.010 |
Why?
|
Topotecan | 1 | 2002 | 131 | 0.010 |
Why?
|
Boston | 1 | 2015 | 9374 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2019 | 4887 | 0.010 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2002 | 108 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20227 | 0.010 |
Why?
|
Transaminases | 1 | 2002 | 199 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2008 | 2732 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2017 | 3415 | 0.010 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2002 | 121 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 4063 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2002 | 748 | 0.010 |
Why?
|
Medicare | 1 | 2019 | 6809 | 0.010 |
Why?
|
Pulmonary Embolism | 1 | 2014 | 2599 | 0.010 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2002 | 590 | 0.010 |
Why?
|
Exons | 1 | 2006 | 2394 | 0.010 |
Why?
|
Phenotype | 1 | 2018 | 16726 | 0.010 |
Why?
|
Plasmids | 1 | 2005 | 2269 | 0.010 |
Why?
|
Endothelial Growth Factors | 1 | 2002 | 671 | 0.010 |
Why?
|
Drug Combinations | 1 | 2006 | 2089 | 0.010 |
Why?
|
Blood Platelets | 1 | 2010 | 2479 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2018 | 22379 | 0.010 |
Why?
|
Pharmacogenetics | 1 | 2004 | 683 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2012 | 4206 | 0.010 |
Why?
|
Lymphokines | 1 | 2002 | 924 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2010 | 2235 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2006 | 3772 | 0.010 |
Why?
|
Cladribine | 1 | 1999 | 34 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 13053 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2009 | 3228 | 0.010 |
Why?
|
Stromal Cells | 1 | 2004 | 1336 | 0.010 |
Why?
|
Vitamin D | 1 | 2012 | 3311 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2005 | 1854 | 0.010 |
Why?
|
Anticoagulants | 1 | 2014 | 4852 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2002 | 2300 | 0.010 |
Why?
|
Hematopoietic Stem Cells | 1 | 2010 | 3409 | 0.010 |
Why?
|
Sex Factors | 1 | 2012 | 10632 | 0.010 |
Why?
|
Creatinine | 1 | 2002 | 1918 | 0.010 |
Why?
|
Lymphoma | 1 | 2005 | 1898 | 0.010 |
Why?
|
Stem Cells | 1 | 2009 | 3537 | 0.010 |
Why?
|
Apoptosis | 1 | 2011 | 9523 | 0.010 |
Why?
|
Cytokines | 1 | 2010 | 7453 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2005 | 2810 | 0.010 |
Why?
|
Dexamethasone | 1 | 2002 | 1965 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4580 | 0.010 |
Why?
|
Syndrome | 1 | 2001 | 3272 | 0.010 |
Why?
|
HIV Infections | 1 | 2000 | 17569 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2012 | 18349 | 0.010 |
Why?
|
Methotrexate | 1 | 1999 | 1721 | 0.010 |
Why?
|
Contrast Media | 1 | 2005 | 5330 | 0.010 |
Why?
|
Kidney | 1 | 2007 | 7064 | 0.010 |
Why?
|
Algorithms | 1 | 2011 | 14164 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2002 | 9615 | 0.000 |
Why?
|
Child | 1 | 2011 | 80917 | 0.000 |
Why?
|